Trial record 1 of 8 for:    TL32711
Previous Study | Return to List | Next Study

Dose Escalation, Combination Chemotherapy Safety Study of TL32711, in Subjects With Advanced or Metastatic Solid Tumors

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
TetraLogic Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01188499
First received: August 23, 2010
Last updated: June 12, 2013
Last verified: June 2013

August 23, 2010
June 12, 2013
October 2010
August 2012   (final data collection date for primary outcome measure)
Number of subjects with adverse events as a measure of safety and tolerability [ Time Frame: 1 Cycle (3-4 weeks) ] [ Designated as safety issue: Yes ]
Number of subjects with adverse events as a measure of safety and tolerability including changes in vital signs, electrocardiograms (ECGs), safety and laboratory parameters
Same as current
Complete list of historical versions of study NCT01188499 on ClinicalTrials.gov Archive Site
  • Evaluation of anti-tumor efficacy [ Time Frame: Every 2 cycles ] [ Designated as safety issue: No ]
    Tumor burden according to Response Evaluation Criteria in Solid Tumors (RECIST) and time to progression
  • Evaluation of pharmacokinetics and translational biomarkers [ Time Frame: Cycle 1 and Cycle 2 ] [ Designated as safety issue: No ]
    Measurement of TL32711 pharmacokinetics: Maximum plasma concentration (Cmax), area under the curve (AUC), half-life (t1/2) and assessment of translational biomarkers in plasma, PBMC's and tumor biopsies. Gene expression profiling of tumor tissue.
  • Evaluation of anti-tumor efficacy [ Time Frame: Every 2 cycles ] [ Designated as safety issue: No ]
    Tumor burden according to Response Evaluation Criteria in Solid Tumors (RECIST)
  • Evaluation of pharmacokinetics and translational biomarkers [ Time Frame: Cycle 1 and Cycle 2 ] [ Designated as safety issue: No ]
    Measurement of TL32711 pharmacokinetics (Cmax, AUC, t1/2) and assessment of translational biomarkers in plasma and blood
Not Provided
Not Provided
 
Dose Escalation, Combination Chemotherapy Safety Study of TL32711, in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors

This is a dose escalation safety study of TL32711 in combination with chemotherapy in subjects with advanced or metastatic solid tumors.

The purpose of this study is to determine the safety and maximum tolerated dose of TL32711 as a 30 minute intravenous infusion once a week, for 2 consecutive weeks, when combined with standard regimens of chemotherapy in subjects with advanced or metastatic solid tumors. Additionally the study will assess anti-tumor activity, pharmacokinetics, and exploratory biomarkers as a measurement of pharmacodynamic effects.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Cancer
  • Drug: TL32711
    30 minute intravenous (IV) infusion of TL32711 administered once weekly for two consecutive weeks followed by one week off repeated every 3 weeks as tolerated in combination with chemotherapy
    Other Names:
    • Paraplatin
    • Taxol
    • Camptosar
    • Taxotere
  • Drug: TL32711
    30 minute intravenous (IV) infusion of TL32711 administered once weekly for two consecutive weeks followed by two weeks off repeated every 4 weeks as tolerated in combination with chemotherapy.
    Other Names:
    • Gemzar
    • Doxil
  • Experimental: Carboplatin/Paclitaxel + TL32711
    Carboplatin (AUC 6/Paclitaxel (175 mg/m2/IV) once every 3 (q3) weeks + TL32711 once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
    Intervention: Drug: TL32711
  • Experimental: Irinotecan + TL32711
    Irinotecan (350 mg/m2/IV) once every 3 (q3) weeks + TL32711 once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
    Intervention: Drug: TL32711
  • Experimental: Docetaxel + TL32711
    Docetaxel (75 mg/m2/IV) once every 3 (q3) weeks + TL32711 once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
    Intervention: Drug: TL32711
  • Experimental: Gemcitabine + TL32711
    Gemcitabine (1000 mg/m2/IV) once weekly (7 days +/- 2 days) for 3 consecutive weeks followed by 1 week off + TL32711 once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 week off for each cycle (4 weeks per cycle).
    Intervention: Drug: TL32711
  • Experimental: Liposomal doxorubicin
    Liposomal doxorubicin (40 mg/m2/IV) every 4 weeks + TL32711 once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 weeks off for each cycle (4 weeks per cycle).
    Intervention: Drug: TL32711
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
200
December 2013
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed advanced or metastatic malignancy for which the proposed chemotherapy regimen is appropriate in the judgment of the Investigator.
  • Prior therapy in dose-escalation and expansion cohorts:

    • Dose-escalation cohorts: Subjects may be naïve or may have received prior therapy with the specific chemotherapeutic agent(s) being recommended in the combination arm, provided the subject did not experience life-threatening toxicity attributed to the specific agent(s).
    • Expansion cohorts: Subjects may not have received prior therapy with the specific combination chemotherapeutic agent(s) in the expansion arm. No more than 2 prior cytotoxic chemotherapy regimens for advanced or metastatic disease are allowed.
  • Subjects evaluated for Arm 5 (liposomal doxorubicin) may not have received >300 mg/m2 cumulative dose of anthracycline.
  • Life expectancy >3 months.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
  • Adequate renal function
  • Adequate hepatic function
  • Adequate bone marrow function
  • Women of childbearing potential must have a negative serum pregnancy test.
  • Women of childbearing potential must agree to use 2 methods of adequate contraception (ie, hormonal and barrier method) prior to enrollment, during the study, and for a period of 30 days following the last dose of TL32711. Males who are sexually active must agree to use a condom during the study and for a period of 30 days following the last dose of TL32711, and if their partner is of childbearing potential, she must agree to use a secondary method of contraception (ie, hormonal, intrauterine device, barrier) during the study and for a period of 30 days following the last dose of TL32711.

Exclusion Criteria:

  • Recent anti-cancer treatment defined as:
  • Standard or investigational anti-cancer therapy within 4 weeks prior to first dose of TL32711. Exception: continued hormonal interventions for prostate cancer.
  • Radiation therapy within 2 weeks prior to the first dose of TL32711.
  • Major surgery within 4 weeks prior to the first dose of TL32711. Subjects must be well recovered from acute effects of surgery prior to enrollment.
  • Known or suspected diagnosis of human immunodeficiency virus or chronic active Hepatitis B or C.
  • Symptomatic or uncontrolled brain metastases requiring current treatment.
  • Impaired cardiac function or clinically significant cardiac disease including the following:
  • QT interval corrected for heart rate (QTcB) >480 msec (including subjects on medication).
  • Lack of recovery of prior adverse events to Grade ≤1 severity (NCI CTCAE v4) (except alopecia) due to therapy administered prior to the initiation of study drug dosing.
  • Nursing or pregnant women.
  • Known allergy to any of the formulation components of TL32711.
  • Any concurrent disease and/or medical condition that in the opinion of the Investigator that would prevent the subject's participation, render the subject at excessive risk (including excessive risks due to the toxicity profile of the planned combination chemotherapeutic regimen), or limit the subject's compliance with the protocol's required evaluations.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01188499
TL32711-POC-0078-PTL
No
TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals
Not Provided
Principal Investigator: Neil N Senzer, MD Mary Crowley Medical Research Center
Principal Investigator: Ravi Amaravadi, MD University of Pennsylvania, Abramson Cancer Center
Principal Investigator: Lainie P Martin, MD Fox Chase Cancer Center
Principal Investigator: Alex Adjei, MD, PhD Roswell Park Cancer Institute
Principal Investigator: Patricia LoRusso, DO Barbara Ann Karmanos Cancer Center
Principal Investigator: Kyriakos P Papadopoulos, MD South Texas Accelerated Research Therapeutics (START)
TetraLogic Pharmaceuticals
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP